The Yawkey building entrance is now closed.

As of April 29, BMC’s Yawkey building doors are closed as an entrance. All patients and visitors on our main campus must enter the hospital via the Shapiro, Menino, or Moakley buildings, where they will be greeted by team members at a new centralized check-in desk. Learn more.

SAGE 547-302

Select your language:

SAGE 547-302: To Evaluate Open-Label Use of SAGE-547 (Allopregnanolone) in the Treatment of Subjects with Super-Refractory Status Epilepticus

Supported by: SAGE

Principal Investigator at BMC: Anna Cervantes-Arslanian, MD

Inclusion Criteria:

Subjects who have:

  1. Failed to respond to the administration of at least one first-line agent (eg, benzodiazepine or other emergent initial AED treatment), according to the institution’s standard of care, and;
  2. Failed to respond to at least one second-line agent (eg, phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam, or other urgent control AEDs), according to the institution’s standard of care, and;
  3. Not previously been administered a third-line agent, but have been admitted to an ICU with the intent of administering at least one third-line agent for at least 24 hours; or who have previously failed one or more wean attempts from third-line agents and are now on continuous intravenous infusions of one or more third-line agents and in an EEG burst suppression pattern; or who have previously failed one or more wean attempts from third-line agents and are now either not on at least one continuous infusion of a third-line agent or are on one or more continuous infusions of third-line agents, but not in an EEG burst suppression pattern.

Exclusion Criteria: 

  1. Subjects who are pregnant;
  2. Subjects with a known allergy to progesterone or allopregnanolone or any excipients in SAGE-547;
  3. Subjects with SRSE due to anoxic/hypoxic encephalopathy;
  4. Subjects who have any of the following:
    a.    GFR low enough to warrant dialysis but for whatever reason, dialysis that would adequately remove Captisol is not planned;
    b.    Severe cardiogenic or vasodilatory shock requiring 2 or more pressors that is not related to third-line agent use;
    c.    Fulminant hepatic failure;
    d.    No reasonable expectation of recovery (for instance, a likely outcome is persistent vegetative state) or life-expectancy, in the opinion of the investigator, of less than 30 days;
    e.    Do not resuscitate (DNR) order;
  5. Subjects who are being administered more than 3 third-line agents concomitantly or in whom the qualifying wean cannot be completed within 24 hours; or who are being administered a third-line agent for other indications such as raised intra-cranial pressure that would preclude weaning according to this protocol;
  6. Subjects with a living will that does not allow heroic measures;
  7. Subjects who have been exposed to an investigational medication or device within 30 days; the exception to this is that participation in the Established Status Epilepticus Treatment Trial or ESETT within 30 days of screening for Study 547-SSE-302 is allowed;
  8. Subjects who have been treated with study drug or randomized in this or any other trial employing SAGE-547 previously;
  9. Subjects for whom it is not medically feasible to be transferred to a geographically accessible participating clinical trial site for Study 547-SSE-301.